In vitro antimyeloma activity of the iron chelator deferasirox (DFX).

被引：0
|
作者：
Willenbacher, Ella [1 ]
Willenbacher, Wolfgang [1 ]
Funk, Ulrike [1 ]
Kircher, Brigitte [1 ]
机构：
[1] Med Univ Innsbruck, A-6020 Innsbruck, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19587
引用
收藏
页数：1
相关论文
共 50 条
  • [21] EXPERIENCE WITH THE IRON-CHELATOR DEFERASIROX IN SRI LANKAN PATIENTS WITH THALASSEMIA
    Olivieri, Nancy
    Chandrakumaran, Priya
    Jayawardena, Sanasi
    Sabouhanian, Amir
    Premawardhena, Anuja
    Mettananda, Sachith
    Senadeera, Dulanjalee
    Wadanamby, Sandara
    Walgamage, Malsha
    Walgamage, Thilini
    Seneviratne, Prarthana
    Silva, I.
    Hameed, N.
    Bandara, Dayananda
    Nimal, J. M.
    Chan, Helen
    Shanmugananatham, Saambavy
    Deb, Bhumika
    Yamashita, Robert
    Rees, David
    Allen, Angela
    Weatherall, David
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [22] In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus
    G. P. Neupane
    D.-M. Kim
    European Journal of Clinical Microbiology & Infectious Diseases, 2010, 29 : 407 - 410
  • [23] In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus
    Neupane, G. P.
    Kim, D-M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2010, 29 (04) : 407 - 410
  • [24] Deferasirox: An effective once-daily orally active iron chelator
    Porter, John B.
    DRUGS OF TODAY, 2006, 42 (10) : 623 - 637
  • [25] Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
    Yamamoto, Naoki
    Yamasaki, Takahiro
    Takami, Taro
    Uchida, Koichi
    Fujisawa, Koichi
    Matsumoto, Toshihiko
    Saeki, Issei
    Terai, Shuji
    Sakaida, Isao
    JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2016, 58 (03) : 202 - 209
  • [26] In Vitro Antioxidant Activity of the Iron Chelator Caffeic Acid: Mechanistic Considerations
    Genaro-Mattos, Thiago Cardoso
    Mauricio, Angelo Queiroz
    Rettori, Daniel
    Vautier-Giongo, Carolina
    Alonso, Antonio
    Hermes-Lima, Marcelo
    FREE RADICAL BIOLOGY AND MEDICINE, 2008, 45 : S82 - S82
  • [27] Deferasirox, an iron chelator, impacts myeloid differentiation by modulating NF-kB activity via mitochondrial ROS
    Jeffries, Nathan E.
    Sadreyev, Daniel
    Trull, Elizabeth C.
    Chetal, Kashish
    Yvanovich, Emma E.
    Mansour, Michael K.
    Sadreyev, Ruslan I.
    Sykes, David B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024,
  • [28] Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models
    Imai, Takahiko
    Tsuji, Shohei
    Matsubara, Hirohumi
    Ohba, Takuya
    Sugiyama, Tomoki
    Nakamura, Shinsuke
    Hara, Hideaki
    Shimazawa, Masamitsu
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (01) : 73 - 84
  • [29] Immunological Evialuation of β-Thalassemia Major Patients Receiving Oral Iron Chelator Deferasirox
    Aleem, Aamer
    Shakoor, Zahid
    Alsaleh, Khalid
    Algahtani, Farjah
    Iqbal, Zafar
    Al-Momen, Abdulkareem
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2014, 24 (07): : 467 - 471
  • [30] Growth Inhibition of Human Breast Cancer Cells with an Iron Chelator (Deferasirox) and Docetaxel
    Lipton, A.
    Witters, L.
    Nick, H.
    CANCER RESEARCH, 2009, 69 (24) : 790S - 790S
12345